The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial
Abstract
Objectıve: The aim of the study is to investigate the effect of myo-inositol (MYO) on pregnancy rates of patients diagnosed with polycystic ovary syndrome (PCOS) who undergone controlled ovulation induction and intrauterine insemination (IUI). METHODS: A total of 196 infertile patients diagnosed with PCOS and admitted to Dokuz Eylul University Faculty of Medicine were included in the study between March 2013 and May 2016. The patients in group 1 (n = 98) were given 4 g MYO and 400 μg folic acid before and during ovulation induction. The patients undergone controlled ovarian hyperstimulation (COH) with recombinant FSH and IUI. The patients in group 2 (n = 98), were given recombinant FSH directly and 400 μg folic acid. The primary outcome measure of this study was the clinical pregnancy rate. RESULTS: In group 1, 9 patients conceived spontaneous pregnancy. During COH + IUI treatment three cycles were canceled in group 1 and 8 cycles in group 2. Total rFSH dose and cycle duration were significantly lower and clinical pregnancy rates were higher in group 1. The pregnancy rate for group 1 was %18.6 and for group 2 was %12.2. Conclusıons: This study shows that MYO should be considered in the treatment of infertile PCOS patients. MYO administration increases clinical pregnancy rates, lowers total rFSH dose and the duration of the ovulation induction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ten studies specifically enrolled women with PCOS who also had infertility (25, 27, 40, 46-51, 55, 56).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [46]
In the citing paper
“These studies used co-interventions of fertility treatment, either ovulation induction with letrozole (49), gonadotropin (50), or gonadotropin and intrauterine insemination (46) or in vitro fertilization (IVF) with or without intracytoplasmic sperm injection (ICSI) (25, 27, 40, 47, 48, 51, 55).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [46]
In the citing paper
“Ten used FA at doses ranging from 200 to 400 mcg daily (25, 27, 29, 31, 34, 37, 46-49).”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [46]
In the citing paper
“The dose of MI used was 4 g daily in 6 of the studies (25, 31, 46-49) with 200 to 400 mcg of FA.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [46]
In the citing paper
“There were 8 studies (25, 27, 31, 34, 46-49) that compared MI + FA to FA alone.”
From Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines (2024) · cites this paper as [46]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
3 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 3×
“Like this study, Morgante [10] and Papaleo [22] found less cancelation rate in patients who were given MYO.”
ResultRetracted- Retracted
RETRACTED: Treatment of hirsutism with myo-inositol: a prospective clinical study
Minozzi, M., D'Andrea, G., & Unfer, V. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60248-9 · Cited by 56
RetractedEpidemiology, diagnosis, and management of polycystic ovary syndrome
Sirmans, S., & Pate, K. (2013) · Clinical Epidemiology · doi:10.2147/clep.s37559 · Cited by 1,302
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
The pathophysiology of polycystic ovary syndrome
Tsilchorozidou, T., Overton, C., & Conway, G. S. (2004) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01842.x · Cited by 294
Genazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221
Chiu, T. T. Y., Rogers, M. S., Law, E. L. K., Briton-Jones, C. M., Cheung, L. P., & Haines, C. J. (2002) · Human Reproduction · doi:10.1093/humrep/17.6.1591 · Cited by 182
Polycystic Ovary Syndrome: A Syndrome of Ovarian Hypersensitivity to Insulin?
Baillargeon, J.-P., & Nestler, J. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1804 · Cited by 169
Artini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743020 · Cited by 154
Research works printed but not linked: 5
- Sirmans SM, 2003, Clin Epidemiol, 6, 1
- Rotterdam ESHRE/ARSM-Sponsored PCOS Consensus Workshop Group, 2004, Fertil Steril, 19
- Alexander CJ, 2009, Rev Cardiovasc Med, 10, 83
- Gerli E, 2007, Eur Rew Med Pharmacol Sci, 11, 347
- Ciotta L, 2011, Eur Rev Med Pharmacol Sci, 15, 509
Cited by
Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites
Chen, W., & Pang, Y. (2021) · Metabolites · doi:10.3390/metabo11120869 · Cited by 228
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach
Laganà, A. S., Garzon, S., Casarin, J., Franchi, M. P., & Ghezzi, F. (2018) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2018.09.001 · Cited by 197
Infertility management in women with polycystic ovary syndrome: a review
Cunha, A., & Póvoa, A. M. (2021) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000116 · Cited by 174
Inositols in polycystic ovary syndrome: An overview on the advances
Facchinetti, F., Unfer, V., Dewailly, D., Kamenov, Z. A., Diamanti-Kandarakis, E., Laganà, A. S., Nestler, J. E., & Soulage, C. O. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.002 · Cited by 102
Metadata
- Authors
- Emekçi Özay, Ö., Özay, A. C., Çağlıyan, E., Okyay, R. E., & Gülekli, B.
- Affiliations
- Department of Obstetrics and Gynecology, Konya Aksehir State Hospital, Konya, Turkey and
- Dokuz Eylül University (TR)
- Venue
- Gynecological Endocrinology
- Publisher
- Informa UK Limited
- Published
- 2017-03-03
- Volume
- 33
- Issue
- 7
- Pages
- 524-528
- ISSN
- 0951-3590 (ISSN-L)
- 1473-0766
- OpenAlex
- W2616274339
- Cited by
- 49
- References
- 23
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 2 · 2023: 8 · 2022: 6 · 2021: 6 · 2020: 7 · 2019: 5 · 2018: 3 · 2017: 2
- FWCI
- 5.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Gynecological Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Keywords
- myo-inositol, polycystic ovary syndrome, ovulation induction, intrauterine insemination, controlled ovarian stimulation, recombinant FSH, clinical pregnancy rate, infertility, folic acid
- MeSH terms
- Adult, Female, Fertility Agents, Female, Follicle Stimulating Hormone, Humans, Inositol, Insemination, Artificial, Ovulation Induction, Polycystic Ovary Syndrome, Pregnancy, Prospective Studies, Treatment Outcome, Pregnancy Rate, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. https://app.cochat.ai/papers/10.1080/09513590.2017.1296127
- The paper
- Emekçi Özay, Ö., Özay, A. C., Çağlıyan, E., Okyay, R. E., & Gülekli, B. (2017). Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial. Gynecological Endocrinology. https://doi.org/10.1080/09513590.2017.1296127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.